These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3087438)
1. DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times. Marti GE; Rick ME; Sidbury J; Gralnick HR Blood; 1986 Jul; 68(1):180-4. PubMed ID: 3087438 [TBL] [Abstract][Full Text] [Related]
2. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation. Kinoshita S; Yoshioka K; Kasahara M; Takamiya O Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773 [TBL] [Abstract][Full Text] [Related]
3. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532 [TBL] [Abstract][Full Text] [Related]
4. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Watson AJ; Keogh JA Nephron; 1982; 32(1):49-52. PubMed ID: 6817151 [TBL] [Abstract][Full Text] [Related]
5. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Sakariassen KS; Cattaneo M; vd Berg A; Ruggeri ZM; Mannucci PM; Sixma JJ Blood; 1984 Jul; 64(1):229-36. PubMed ID: 6428488 [TBL] [Abstract][Full Text] [Related]
6. Use of DDAVP in inherited and acquired platelet dysfunction. DiMichele DM; Hathaway WE Am J Hematol; 1990 Jan; 33(1):39-45. PubMed ID: 2293761 [TBL] [Abstract][Full Text] [Related]
7. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. Holmberg L; Nilsson IM; Borge L; Gunnarsson M; Sjörin E N Engl J Med; 1983 Oct; 309(14):816-21. PubMed ID: 6412139 [TBL] [Abstract][Full Text] [Related]
8. Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin. Kim HC; Salva K; Fallot PL; Karp GI; Eisele J; Matts L; Heller I; Saidi P Thromb Haemost; 1988 Apr; 59(2):221-4. PubMed ID: 3388295 [TBL] [Abstract][Full Text] [Related]
9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
10. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis. Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Kentro TB; Lottenberg R; Kitchens CS Am J Hematol; 1987 Feb; 24(2):215-9. PubMed ID: 3101493 [TBL] [Abstract][Full Text] [Related]
12. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
13. [Desmopressin in the treatment of hemorrhagic diathesis]. Haar D; Hasselbalch HC Ugeskr Laeger; 1995 Nov; 157(48):6713-5. PubMed ID: 8540136 [TBL] [Abstract][Full Text] [Related]
14. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease patient. Casonato A; Fabris F; Girolami A Eur J Haematol; 1990 Jul; 45(1):36-42. PubMed ID: 2116314 [TBL] [Abstract][Full Text] [Related]
15. Desmopressin: a nontransfusional hemostatic agent. Mannucci PM Annu Rev Med; 1990; 41():55-64. PubMed ID: 2184748 [TBL] [Abstract][Full Text] [Related]
16. Response to desmopressin in type IID von Willebrand's disease. Thomas N; O'Callaghan U; Lowe GD; Olszynski V; Kernoff PB; Abildgaard CF; Tuddenham EG Clin Lab Haematol; 1989; 11(3):189-97. PubMed ID: 2591151 [TBL] [Abstract][Full Text] [Related]
17. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. Favaloro EJ; Dean M; Grispo L; Exner T; Koutts J Am J Hematol; 1994 Mar; 45(3):205-11. PubMed ID: 8296790 [TBL] [Abstract][Full Text] [Related]
18. Acquired von Willebrand's disease in the myeloproliferative syndrome. Budde U; Schaefer G; Mueller N; Egli H; Dent J; Ruggeri Z; Zimmerman T Blood; 1984 Nov; 64(5):981-5. PubMed ID: 6333259 [TBL] [Abstract][Full Text] [Related]
19. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Pfueller SL; Howard MA; White JG; Menon C; Berry EW Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198 [TBL] [Abstract][Full Text] [Related]
20. Experience of desmopressin (DDAVP) administration in patients with congenital and acquired bleeding disorders. Tsay W; Shen MC J Formos Med Assoc; 1992 Oct; 91(10):962-9. PubMed ID: 1362675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]